Connect with us

Hi, what are you looking for?

DOGE0.070.84%SOL19.370.72%USDC1.000.01%BNB287.900.44%AVAX15.990.06%XLM0.080.37%
USDT1.000%XRP0.392.6%BCH121.000.75%DOT5.710.16%ADA0.320.37%LTC85.290.38%
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

Pfizer Fined for Raising Drug Prices

Recently the U.S. Pharmaceutical company Pfizer is being fined $106 million for raising the prices of anti-epilepsy medication a record of 2,600%. According to British regulator Competition and Markets Authority, the New York-based company overcharged patients for phenytoin sodium capsules, a drug that had been de-banded around September 2012.

Although Pfizer said that it’s going to appeal the fine, the price of the epilepsy drug capsules skyrocketed from $3.75 for 100 milligrams to $85.06. Even though the price was ultimately dropped to around $68 in May. This caused prices for the National Health Care Service in Britain to rise to $2 million in 2012 and $63 million in 2013.

Pfizer claims that the drug was a “loss” for the CMA, but the company disagrees. Chairman of the CMA, Philip Marsden, said in a statement, “Businesses are generally free to set prices as they see fit but those holding a dominant position should not abuse this situation and set prices that are excessive and unfair.” The regulator even went as far as to give Pfizer up to four months to change the prices on the sodium capsules.

Pfizer isn’t the only company under investigation for the recent spike in pharmaceutical drug prices. Mylan’s prices for EpiPen, a medication used by patients to reduce allergic reactions, rose from $100 to $600 for a two-pack.  Pfizer did, however, say in a statement that they felt the fine “highlights real policy and legal issues concerning the respective roles of both the Department of Health and the CMA, in regulating the price of pharmaceutical products in the U.K.”


Comment Template

You May Also Like

Business

Britain’s Ambitious Strategy to Strengthen Nuclear Workforce Prime Minister Rishi Sunak is poised to unveil strategies aimed at bolstering Britain’s nuclear workforce, responding to...

Business

Pfizer forecasts 2024 revenue below Wall Street expectations. On Wednesday, Pfizer (PFE.N) announced that it would be lowering its cost-cutting objective by $500 million...

AI

On Sunday, the U.S., Britain, and more than a dozen other nations unveiled the first detailed international agreement on protecting AI from rogue actors,...

Economy

Four Japanese sources stated Japan, Britain, and Italy would base their next-generation fighter program in Britain, putting London at the forefront of a collaboration...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok